This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Casanova, A.
Right arrow Articles by Díaz, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casanova, A.
Right arrow Articles by Díaz, R.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, June 2009, p. 844-851, Vol. 16, No. 6
1071-412X/09/$08.00+0     doi:10.1128/CVI.00348-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

BrucellaCapt versus Classical Tests in the Serological Diagnosis and Management of Human Brucellosis{triangledown}

Aurora Casanova,1* Javier Ariza,2 Manuel Rubio,3 Cristina Masuet,4 and Ramón Díaz3

Department of Microbiology,1 Department of Infectious Diseases,2 Department of Preventive Medicine, Hospital Universitari de Bellvitge, Universidad de Barcelona, IDIBELL, L'Hospitalet de Llobregat, Barcelona,4 Department of Microbiology, Clinica Universitaria de Navarra, Pamplona, Spain3

Received 31 July 2008/ Returned for modification 24 November 2008/ Accepted 7 April 2009

The BrucellaCapt test is an immunocapture agglutination test suggested as a possible substitute for the Coombs test in the diagnosis of human brucellosis. Here it is compared with classical tests using 321 samples from 48 patients with brucellosis (6.9 ± 1.7 samples per patient), including 20 patients with focal disease and 8 patients with a total of 9 relapse episodes (mean follow-up, 18 months). The BrucellaCapt test was used according to the manufacturer's instructions, and we also used a variant of the BrucellaCapt test in which the microtiter plates were not coated with antibodies against total human immunoglobulin (BCAPV). The correlation between the BrucellaCapt and BCAPV tests was 0.982 (P < 0.001), with 260 coincident pairs of titers (81%). The areas under the receiver operating characteristic curve for the BrucellaCapt and BCAPV tests with respect to the Coombs test were 0.969 and 0.960, respectively. Upon admission, the BrucellaCapt, BCAPV, and Coombs tests and the microagglutination test (MAT) were positive for all cases: titers were 1/2,560 by the BrucellaCapt test, 1/2,560 by the BCAPV test, 1/1,280 by the Coombs test, and 1/320 by the MAT. The decreases in the BrucellaCapt and BCAPV titers over time were pronounced in comparison with the Coombs titers. Cumulative probabilities of persistence 12 months after therapy were as follows: 80% by the BrucellaCapt test, 80% by the BCAPV test, 87% by the Coombs test, and 35% by the MAT. Serological changes during relapse were detected in seven cases (88%) by the Coombs test, in five cases by the BrucellaCapt and BCAPV tests, and in three cases by the MAT. The BrucellaCapt test is a sensitive, specific, and simple test for routine use in human brucellosis. Similar results were obtained with the BCAPV test. However, in some cases of relapse and chronic forms of the disease, the slight changes observed in low-affinity antibodies alone are better detected by the Coombs test.

* Corresponding author. Mailing address: Department of Microbiology, Hospital Universitari de Bellvitge, c/Feixa Llarga s/n. 08907, L'Hospitalet de LLobregat, Barcelona, Spain. Phone: 34-932607930. Fax: 34-932607547. E-mail: acasanova{at}bellvitgehospital.cat

{triangledown} Published ahead of print on 15 April 2009.

Clinical and Vaccine Immunology, June 2009, p. 844-851, Vol. 16, No. 6
1071-412X/09/$08.00+0     doi:10.1128/CVI.00348-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»